

2024 Area of Interest for Pneumococcus

Pneumococcus Areas of Interest

Effective February 23, 2024, the Pneumococcus Investigator-Initiated Studies Program (MISP) Committee will accept protocols within our current Areas of Interest (Aols). This is a competitive process that will be conducted by the Pneumococcus MISP Review Committee. Decisions will be made on the basis of scientific merit and strategic fit within the Aols. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

1. V114:PCV15 studies including impact on:

- a. The paediatric population including but not limited to high-risk infants/toddlers/young children
- b. Nasopharyngeal carriage and AOM
- c. Infants/toddlers/young children on biologics, rheumatology patients, and those with immunologic diseases
- d. Viral co-infection

2. Studies refining correlates of protection and endpoints in both pediatric and adult populations

3. Studies supporting V116 (after regulatory approval) including:

- a. Serotype coverage and burden of disease
- b. Nasopharyngeal carriage
- c. Impact on pneumonia
- d. Impact beyond *S. pneumoniae*

e. Serotype-specific urinary antigen detection studies

4. Mucosal delivery of pneumococcal vaccines (capsular and/or protein antigens) in pediatric and/or adult populations

5. Impact of pneumococcal vaccines (V114:PCV15) on the microbiome in pediatric and/or adult populations

6. Impact of pneumococcal vaccines (V114:PCV15) on antimicrobial resistance in pediatric and/or adult populations